BR112013001303A2 - métodos de uso de derivados de amida cíclica para tratar esquizofrenia - Google Patents

métodos de uso de derivados de amida cíclica para tratar esquizofrenia

Info

Publication number
BR112013001303A2
BR112013001303A2 BR112013001303A BR112013001303A BR112013001303A2 BR 112013001303 A2 BR112013001303 A2 BR 112013001303A2 BR 112013001303 A BR112013001303 A BR 112013001303A BR 112013001303 A BR112013001303 A BR 112013001303A BR 112013001303 A2 BR112013001303 A2 BR 112013001303A2
Authority
BR
Brazil
Prior art keywords
methods
amide derivatives
cyclic amide
schizophrenia
treat schizophrenia
Prior art date
Application number
BR112013001303A
Other languages
English (en)
Portuguese (pt)
Inventor
Argeris N Karabelas
Lorenzo Pellegrini
Remy Henri Luthringer
Original Assignee
Cyrenaic Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyrenaic Pharmaceuticals Inc filed Critical Cyrenaic Pharmaceuticals Inc
Publication of BR112013001303A2 publication Critical patent/BR112013001303A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0003—Two-dimensional division
    • H04L5/0005—Time-frequency
    • H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112013001303A 2010-07-20 2011-07-20 métodos de uso de derivados de amida cíclica para tratar esquizofrenia BR112013001303A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
PCT/US2011/044697 WO2012012542A1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia

Publications (1)

Publication Number Publication Date
BR112013001303A2 true BR112013001303A2 (pt) 2016-05-17

Family

ID=45497166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001303A BR112013001303A2 (pt) 2010-07-20 2011-07-20 métodos de uso de derivados de amida cíclica para tratar esquizofrenia

Country Status (22)

Country Link
US (3) US20180155318A1 (cg-RX-API-DMAC7.html)
EP (4) EP3335731B1 (cg-RX-API-DMAC7.html)
JP (2) JP6053678B2 (cg-RX-API-DMAC7.html)
KR (1) KR101867633B1 (cg-RX-API-DMAC7.html)
CN (1) CN103220910B (cg-RX-API-DMAC7.html)
BR (1) BR112013001303A2 (cg-RX-API-DMAC7.html)
CA (2) CA2806017C (cg-RX-API-DMAC7.html)
DK (2) DK2595484T3 (cg-RX-API-DMAC7.html)
ES (2) ES2963362T3 (cg-RX-API-DMAC7.html)
FI (1) FI3135286T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231446T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064157T2 (cg-RX-API-DMAC7.html)
LT (1) LT3135286T (cg-RX-API-DMAC7.html)
NO (1) NO2595484T3 (cg-RX-API-DMAC7.html)
PL (2) PL3135286T3 (cg-RX-API-DMAC7.html)
PT (2) PT3135286T (cg-RX-API-DMAC7.html)
RS (1) RS64819B1 (cg-RX-API-DMAC7.html)
RU (1) RU2576611C2 (cg-RX-API-DMAC7.html)
SI (1) SI3135286T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300413T1 (cg-RX-API-DMAC7.html)
TW (1) TWI583679B (cg-RX-API-DMAC7.html)
WO (1) WO2012012542A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) * 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
GB202416895D0 (en) * 2024-11-18 2025-01-01 Phytoquest Ltd Treatment of sleep disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
SI3135286T1 (sl) 2024-02-29
DK3135286T3 (da) 2023-11-27
EP2595484A1 (en) 2013-05-29
CA2806017C (en) 2021-06-29
EP4494704A2 (en) 2025-01-22
CA3117855A1 (en) 2012-01-26
RU2013107382A (ru) 2014-08-27
CN103220910B (zh) 2016-05-11
US20180155318A1 (en) 2018-06-07
SMT202300413T1 (it) 2024-01-10
EP3335731A1 (en) 2018-06-20
LT3135286T (lt) 2023-11-10
KR101867633B1 (ko) 2018-06-15
WO2012012542A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
ES2963362T3 (es) 2024-03-26
PT3135286T (pt) 2023-11-28
PT2595484T (pt) 2018-01-22
RS64819B1 (sr) 2023-12-29
PL2595484T3 (pl) 2018-03-30
FI3135286T3 (fi) 2023-11-15
CA3117855C (en) 2023-01-10
EP3335731B1 (en) 2024-09-04
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
CN103220910A (zh) 2013-07-24
EP3135286A1 (en) 2017-03-01
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
NO2595484T3 (cg-RX-API-DMAC7.html) 2018-03-17
JP2017031159A (ja) 2017-02-09
TWI583679B (zh) 2017-05-21
JP6200561B2 (ja) 2017-09-20
EP4494704A3 (en) 2025-04-23
DK2595484T3 (en) 2018-01-22
EP3135286B1 (en) 2023-09-06
HRP20231446T1 (hr) 2024-03-01
US20250179044A1 (en) 2025-06-05
US20220274951A1 (en) 2022-09-01
CA2806017A1 (en) 2012-01-26
EP2595484B1 (en) 2017-10-18
HUE064157T2 (hu) 2024-02-28
PL3135286T3 (pl) 2024-04-22
EP2595484A4 (en) 2014-04-23
RU2576611C2 (ru) 2016-03-10

Similar Documents

Publication Publication Date Title
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
MX2013005549A (es) Aminas heterociclicas y sus usos.
BR112013014119A8 (pt) Novos moduladores e métodos de uso
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
BR112013021134A2 (pt) moduladores e métodos de uso
AR089993A1 (es) Macrociclos peptidomimeticos
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
MX381456B (es) Regulador de ph de transduccion.
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
EA202193044A2 (ru) Способы лечения таупатии
UA115972C2 (uk) Біциклічні похідні дигідрохінолін-2-ону
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201391489A1 (ru) Композиции со сниженной вязкостью
BR112013005116A2 (pt) moduladores e métodos de uso
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201490846A1 (ru) Новые производные арилхинолина
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/40 , A61K 31/445 , C07D 217/00 , C07D 217/02 , C07D 217/22 , C07D 401/00

Ipc: A61K 31/445 (2006.01), C07D 217/00 (2006.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL